Metformin Shows Biological Plausibility for Pregnancy Hypertension, but Clinical Benefit Remains Inconsistent
Hypertensive disorders of pregnancy remain among the most consequential complications in maternal care, with gestational hypertension and preeclampsia driving avoidable morbidity for both mother and fetus. The appeal of metformin in this setting is straightforward: it targets the metabolic terrain that often overlaps with pregnancy hypertension, including insulin resistance, excessive gestational weight gain, inflammation, oxidative stress, endothelial dysfunction, and placental maladaptation. Those pathways are not abstract. They shape vascular tone, placental perfusion, and the maternal response to rising circulatory demands across gestation.
The question has never been whether metformin can change metabolism. The question is whether those metabolic effects translate into fewer hypertensive complications.
A Phenotype-Based Review Drew on Trials, Cohorts, and Mechanistic Studies
This focused narrative review used structured searches across PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar, concentrating mainly on literature published from January 2015 through March 2026. The evidence base was deliberately broad and included landmark studies, clinical guidelines, randomized trials, large observational cohorts, systematic reviews, meta-analyses, and mechanistic and placental investigations. Rather than treating all pregnancies as interchangeable, the review organized the literature around phenotypes in which metabolic dysfunction and hypertensive disorders of pregnancy frequently intersect: gestational diabetes mellitus, type 2 diabetes mellitus, obesity, and polycystic ovary syndrome.
That framework matters because the biology is shared even when the clinical outcomes diverge. Insulin resistance and adiposity can amplify systemic inflammation, alter endothelial signaling, and distort placental development. Metformin has enough pharmacologic reach to plausibly modify those processes, but the downstream effect on blood pressure and preeclampsia has proven far less consistent than the metabolic effect on glucose handling.
Metabolic Effects Are Clearer Than Blood Pressure Effects
Across the reviewed literature, metformin consistently improved insulin sensitivity and appeared to reduce gestational weight gain in some settings. Those changes are not trivial in pregnancy. Less metabolic stress may ease vascular strain, and lower inflammatory signaling may reduce the biochemical pressure on the maternal endothelium. In theory, that should translate into a lower risk of pregnancy-induced hypertension or preeclampsia, especially in women whose baseline risk is already elevated by obesity, GDM, or PCOS.
Several randomized trials and meta-analyses did point in that direction. In those studies, metformin was associated with lower rates of pregnancy-induced hypertension or preeclampsia. Yet the signal was not durable across the full evidence base. Recent randomized and population-based studies reported neutral findings, leaving the overall picture mixed rather than decisive. The inconsistency is clinically important because preeclampsia is not a single disease with a single mechanism; it is a syndrome shaped by placental, vascular, inflammatory, and metabolic influences that do not respond uniformly to one medication.
Why the Signal Fades Across Studies
The variation in outcomes reflects major differences in how the studies were built. Populations were heterogeneous, and treatment often began at different gestational ages. Some cohorts allowed supplemental insulin, which can blunt any distinct effect attributable to metformin alone. Comparators also varied, making cross-study synthesis difficult. Even the definition of hypertensive disorders of pregnancy was not consistent, which complicates endpoint interpretation and weakens pooled conclusions.
Sample size and statistical power also limited several of the included studies. A modest reduction in preeclampsia risk can disappear when the event rate is low, when participants are enrolled late, or when the phenotype mix is too broad. In practical terms, a therapy that may help one metabolic subgroup can look neutral when it is tested in a mixed obstetric population with different baseline risks and different co-interventions.
Placental and Vascular Biology Offer a Rationale, Not a Guarantee
Metformin’s attractiveness in obstetrics rests on its biologic profile. By improving insulin sensitivity, it may lower the metabolic burden that contributes to endothelial dysfunction. Its potential influence on inflammatory signaling and oxidative stress provides another plausible route to vascular benefit. Placental studies suggest that metformin may interact with pathways involved in placental adaptation, but mechanistic plausibility does not guarantee a measurable clinical effect on blood pressure or maternal-fetal outcomes.
That gap between mechanism and endpoint is especially important in pregnancy. Preeclampsia arises from abnormal placentation early in gestation and later maternal vascular dysfunction, so a medication introduced too late may improve weight gain or glycemic control without meaningfully changing the trajectory of placental disease. Once the vascular cascade is established, metabolic correction alone may be too narrow to alter the course.
Routine Use for Preeclampsia Prevention Is Not Supported
The most direct clinical conclusion is restrained. Current evidence does not support routine metformin use specifically for prevention of hypertensive disorders of pregnancy. The review places metformin in a more modest role: a metabolic and vascular modifier in selected pregnancies, not a substitute for established prevention and surveillance strategies. Aspirin prophylaxis, blood pressure monitoring, and maternal-fetal follow-up remain central.
For patients with GDM, obesity, or PCOS, metformin may still be useful as part of broader antenatal care because it addresses glycemic and metabolic risk, and those benefits can matter even when blood pressure outcomes do not change. Its public health value lies in accessibility and in the possibility of integration with postpartum risk reduction, where cardiometabolic risk does not end at delivery.
A one-drug solution for preeclampsia has not emerged here. What remains is a narrower and more disciplined use case: metformin as part of comprehensive metabolic management, with any antihypertensive advantage treated as possible but unproven.
The Remaining Problem Is Selection, Timing, and Endpoints
Future work needs sharper phenotyping, earlier treatment windows, and standardized definitions of hypertensive outcomes. Studies that separate women with GDM from those with obesity or PCOS may clarify whether any subgroup derives a real preventive benefit. Trials will also need to account for insulin co-therapy, baseline cardiometabolic risk, and whether treatment begins before placentation is complete. Without those details, the literature will continue to mix biologically different pregnancies into a single analysis.
The evidence base now supports a careful reading: metformin may improve the metabolic environment of pregnancy, but its effect on preeclampsia prevention remains too inconsistent for routine obstetric use on that indication alone.